Y-Intercept (HK)’s Accelerate Diagnostics AXDX Stock Holding History

Y-Intercept (HK)’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,866	Closed	-$34K	–	1179
2024 Q3	$34K	Buy	+19,866	New	+$29.4K	﹤0.01%	1232

Other funds holding AXDX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cannell & Spears New York $5.62B AUM 41.25% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Y-Intercept (HK)'s AXDX Position: Q4 2024 in Review

Y-Intercept (HK) sold out of Accelerate Diagnostics (AXDX) in Q4 2024, closing a stake of 19,866 shares — an estimated $34K sold.

Y-Intercept (HK) first reported a position in AXDX in Q3 2024 and held it in 1 quarter. The position peaked at $34K in Q3 2024. 47 funds tracked by Wall St. Rank hold AXDX as of Q4 2024.

Y-Intercept (HK) reported no remaining Accelerate Diagnostics position as of Q4 2024 after selling out during the quarter.
Y-Intercept (HK) sold 19,866 Accelerate Diagnostics shares in Q4 2024, an estimated $34K.
Y-Intercept (HK) first reported a position in Accelerate Diagnostics in Q3 2024 and held it in 1 quarter.
Y-Intercept (HK)'s Accelerate Diagnostics position peaked at $34K in Q3 2024.
47 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2024.

Based on Y-Intercept (HK)'s 13F filing for Q4 2024, filed 4 Feb 2025.